Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®
March 11, 2022 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 11, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Recro to Present at H.C. Wainwright BioConnect 2022 Conference
January 03, 2022 07:00 ET
|
Recro Pharma, Inc.
SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex...
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2022 After Market Close on December 7, 2021
November 30, 2021 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Appoints Elie G. Hanania, Ph.D., as Vice President, Process Development, Viral Vector Technologies
November 04, 2021 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Anatomic Pathology Market Size ($33,145.78Mn by 2028) Lead by Services Segment (40.04% Revenue Share in 2021) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
November 02, 2021 13:23 ET
|
The Insight Partners
New York, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Anatomic Pathology Market: Key Insights According to our new research study on Anatomic Pathology Market Size and Forecast to 2028 - COVID-19 Impact and...
Clearmind Medicine Files Provisional Patent Application Related to Methods of Drug-Assisted Psychotherapy
October 13, 2021 08:00 ET
|
Clearmind Medicine
TORONTO, Ontario, Oct. 13, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused...
vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
September 23, 2021 16:30 ET
|
vTv Therapeutics Inc.
HPP737 exhibited favorable safety and tolerability profile, with no dose limiting gastrointestinal side effects Results build on data from previous multiple ascending dose study and support...
Clearmind Medicine Partners with The Hebrew University to Develop Novel Psychedelic Drug
September 21, 2021 07:00 ET
|
Clearmind Medicine
TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery...
Recro Signs Renewable Energy Agreement With Georgia Power
September 21, 2021 07:00 ET
|
Recro Pharma, Inc.
EXTON, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Global Antiviral Therapy Market Expected to Generate a Revenue of $79.8 Million by 2026, Growing at a CAGR of 6.7% From 2019-2026 COVID-19 Impact - Exclusive Report by Research Dive
September 14, 2021 09:01 ET
|
Research Dive
New York, USA, Sept. 14, 2021 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global antiviral therapy market is expected to generate a revenue of $79.8 million by 2026,...